182 related articles for article (PubMed ID: 25145628)
1. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy.
Bernardo BC; Nguyen SS; Winbanks CE; Gao XM; Boey EJ; Tham YK; Kiriazis H; Ooi JY; Porrello ER; Igoor S; Thomas CJ; Gregorevic P; Lin RC; Du XJ; McMullen JR
FASEB J; 2014 Dec; 28(12):5097-110. PubMed ID: 25145628
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-328 as a regulator of cardiac hypertrophy.
Li C; Li X; Gao X; Zhang R; Zhang Y; Liang H; Xu C; Du W; Zhang Y; Liu X; Ma N; Xu Z; Wang L; Chen X; Lu Y; Ju J; Yang B; Shan H
Int J Cardiol; 2014 May; 173(2):268-76. PubMed ID: 24631114
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload.
Bernardo BC; Nguyen SS; Gao XM; Tham YK; Ooi JY; Patterson NL; Kiriazis H; Su Y; Thomas CJ; Lin RC; Du XJ; McMullen JR
Sci Rep; 2016 Mar; 6():22442. PubMed ID: 26928825
[TBL] [Abstract][Full Text] [Related]
5. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy.
Bernardo BC; Gao XM; Tham YK; Kiriazis H; Winbanks CE; Ooi JY; Boey EJ; Obad S; Kauppinen S; Gregorevic P; Du XJ; Lin RC; McMullen JR
PLoS One; 2014; 9(2):e90337. PubMed ID: 24587330
[TBL] [Abstract][Full Text] [Related]
6. Sex differences in response to miRNA-34a therapy in mouse models of cardiac disease: identification of sex-, disease- and treatment-regulated miRNAs.
Bernardo BC; Ooi JY; Matsumoto A; Tham YK; Singla S; Kiriazis H; Patterson NL; Sadoshima J; Obad S; Lin RC; McMullen JR
J Physiol; 2016 Oct; 594(20):5959-5974. PubMed ID: 27270487
[TBL] [Abstract][Full Text] [Related]
7. Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload.
Wu C; Dong S; Li Y
Int J Mol Med; 2015 Apr; 35(4):893-900. PubMed ID: 25695617
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
Li Q; Xie J; Wang B; Li R; Bai J; Ding L; Gu R; Wang L; Xu B
PLoS One; 2016; 11(2):e0148480. PubMed ID: 26914935
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-150 Protects Against Pressure Overload-Induced Cardiac Hypertrophy.
Liu W; Liu Y; Zhang Y; Zhu X; Zhang R; Guan L; Tang Q; Jiang H; Huang C; Huang H
J Cell Biochem; 2015 Oct; 116(10):2166-76. PubMed ID: 25639779
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-21 is involved in direct actions of ursolic acid on the heart: implications for cardiac fibrosis and hypertrophy.
Dong X; Liu S; Zhang L; Yu S; Huo L; Qile M; Liu L; Yang B; Yu J
Cardiovasc Ther; 2015 Aug; 33(4):161-7. PubMed ID: 25903305
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress.
Yuan J; Liu H; Gao W; Zhang L; Ye Y; Yuan L; Ding Z; Wu J; Kang L; Zhang X; Wang X; Zhang G; Gong H; Sun A; Yang X; Chen R; Cui Z; Ge J; Zou Y
Theranostics; 2018; 8(9):2565-2582. PubMed ID: 29721099
[No Abstract] [Full Text] [Related]
12. Exercise preconditioning attenuates pressure overload-induced pathological cardiac hypertrophy.
Xu T; Tang H; Zhang B; Cai C; Liu X; Han Q; Zou L
Int J Clin Exp Pathol; 2015; 8(1):530-40. PubMed ID: 25755743
[TBL] [Abstract][Full Text] [Related]
13. HSF1 and NF-κB p65 participate in the process of exercise preconditioning attenuating pressure overload-induced pathological cardiac hypertrophy.
Xu T; Zhang B; Yang F; Cai C; Wang G; Han Q; Zou L
Biochem Biophys Res Commun; 2015 May; 460(3):622-7. PubMed ID: 25804640
[TBL] [Abstract][Full Text] [Related]
14. AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction.
Hinkel R; Batkai S; Bähr A; Bozoglu T; Straub S; Borchert T; Viereck J; Howe A; Hornaschewitz N; Oberberger L; Jurisch V; Kozlik-Feldmann R; Freudenthal F; Ziegler T; Weber C; Sperandio M; Engelhardt S; Laugwitz KL; Moretti A; Klymiuk N; Thum T; Kupatt C
J Am Coll Cardiol; 2021 Jun; 77(23):2923-2935. PubMed ID: 34112319
[TBL] [Abstract][Full Text] [Related]
15. miR-222 inhibits pathological cardiac hypertrophy and heart failure.
Liu X; Li H; Hastings MH; Xiao C; Damilano F; Platt C; Lerchenmüller C; Zhu H; Wei XP; Yeri A; Most P; Rosenzweig A
Cardiovasc Res; 2024 Mar; 120(3):262-272. PubMed ID: 38084908
[TBL] [Abstract][Full Text] [Related]
16. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
Ganesan J; Ramanujam D; Sassi Y; Ahles A; Jentzsch C; Werfel S; Leierseder S; Loyer X; Giacca M; Zentilin L; Thum T; Laggerbauer B; Engelhardt S
Circulation; 2013 May; 127(21):2097-106. PubMed ID: 23625957
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
[TBL] [Abstract][Full Text] [Related]
18. Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy.
Seok HY; Chen J; Kataoka M; Huang ZP; Ding J; Yan J; Hu X; Wang DZ
Circ Res; 2014 May; 114(10):1585-95. PubMed ID: 24657879
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-31 promotes adverse cardiac remodeling and dysfunction in ischemic heart disease.
Martinez EC; Lilyanna S; Wang P; Vardy LA; Jiang X; Armugam A; Jeyaseelan K; Richards AM
J Mol Cell Cardiol; 2017 Nov; 112():27-39. PubMed ID: 28865712
[TBL] [Abstract][Full Text] [Related]
20. Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs.
Matkovich SJ; Dorn GW; Grossenheider TC; Hecker PA
Circ Cardiovasc Genet; 2015 Dec; 8(6):774-84. PubMed ID: 26553694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
